Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23185465 | 0.91 | MAPT (0.43) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL19726841 | 0.90 | MAPT (0.43) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL24086403 | 0.90 | MAPT (0.50) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL23554179 | 0.89 | TP53 (0.46) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL22336500 | 0.88 | MAPT (0.48) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL21128864 | 0.87 | MAPT (0.43) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL24500277 | 0.85 | MAPT (0.46) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL24715149 | 0.83 | MAPT (0.44) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL16646710 | 0.80 | MAPT (0.49) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL24496995 | 0.80 | MAPT (0.46) | MAPTTP53GAAPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066138-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SHANGHAI RUOTUO BIOSCIENCES CO LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-9981046-B2 | Drug-conjugates, conjugation methods, and uses thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981046-B2 | Drug-conjugates, conjugation methods, and uses thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | SORRENTO THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9884127-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160067350-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | ABCG2, UGT2B7, UGT1A9 | MAPT 1089/4885TP53 2698/4885GAA 180/4885 |
| US-20160067350-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | MAPT 1589/4885TP53 2257/4885GAA 95/4885 |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | ABCG2, UGT2B7, UGT1A9 | MAPT 1089/4885TP53 2698/4885GAA 180/4885 |
| US-20240066138-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | FCGR1A, FCGRT, FCGR2A | MAPT 149/4885TP53 348/4885GAA 51/4885 |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | MAPT 1589/4885TP53 2257/4885GAA 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.